Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Protein Design Labs (PDLI): Stock strong -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (199)	3/21/2002 1:24:43 PM
From: tuck	Read Replies (1) \| Respond to of 407

Today's laugh: >>Protein Design Labs (Nasdaq: PDLI - news) jumped 14.3% to $17.16 on the heels of an upgrade from investment firm Morgan Stanley (NYSE: MWD - news). Yesterday, the company announced that Zenapax, a drug already approved to prevent organ rejection in kidney transplants, failed in early testing as a treatment for psoriasis. Since drugs in the beginning stages of testing don't have much probability of reaching the market, the news doesn't affect Morningstar's fair value, said Morningstar stock analyst Jill Kiersky. The stock is overpriced in Kiersky's view, trading 60% higher than its fair value of $16 per share. For more on this story, read today's Stock Analyst Notes.<< snip, emphasis mine Jill, when you learn how to do arithmetic, maybe we'll listen to you. Cheers, Tuck